About ACD Bio
ACD Bio is a company based in Newark (United States) founded in 2006 was acquired by Bio-Techne in July 2016.. ACD Bio has raised $39.4 million across 8 funding rounds from investors including New Leaf Venture Partners, Bio-Techne and HHS. ACD Bio offers products and services including RNAscope Assay, BaseScope Assay, and miRNAscope Assay. ACD Bio operates in a competitive market with competitors including Abcam, Sino Biological, GenScript, Stem Cell Technologies and Miltenyi Biotec, among others.
- Headquarter Newark, United States
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Advanced Cell Diagnostics, Inc.
-
Annual Revenue
$576.82 K (USD)-41as on Dec 31, 2020
-
Net Profit
$-264.49 K (USD)-3889as on Dec 31, 2022
-
EBITDA
-
Total Equity Funding
$39.4 M (USD)
in 8 rounds
-
Latest Funding Round
$22 M (USD), Series C
Jun 18, 2015
-
Investors
New Leaf Venture Partners
& 7 more
-
Employee Count
Employee Count
-
Acquired by
Bio-Techne
(Jul 06, 2016)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of ACD Bio
ACD Bio offers a comprehensive portfolio of products and services, including RNAscope Assay, BaseScope Assay, and miRNAscope Assay. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Enables visualization of single RNA molecules in tissues.
Detects RNA targets with high sensitivity in research samples.
Facilitates microRNA detection for gene regulation studies.
Funding Insights of ACD Bio
ACD Bio has successfully raised a total of $39.4M across 8 strategic funding rounds. The most recent funding activity was a Series C round of $22 million completed in June 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 8
- Last Round Series C — $22.0M
-
First Round
First Round
(05 Sep 2006)
- Investors Count 7
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2015 | Amount | Series C - ACD Bio | Valuation | Summit Partners | |
| Oct, 2014 | Amount | Grant - ACD Bio | Valuation |
investors |
|
| Nov, 2012 | Amount | Series B - ACD Bio | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in ACD Bio
ACD Bio has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include New Leaf Venture Partners, Bio-Techne and HHS. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Stage-agnostic investments in US life sciences are managed.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
Summit Partners is recognized as a growth equity investment firm.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by ACD Bio
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - ACD Bio
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Acd Bio Comparisons
Competitors of ACD Bio
ACD Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Abcam, Sino Biological, GenScript, Stem Cell Technologies and Miltenyi Biotec, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Biological reagents and antibodies are developed for life science research.
|
|
| domain | founded_year | HQ Location |
Reagents and kits are provided for clinical research applications.
|
|
| domain | founded_year | HQ Location |
Reagents and instruments are provided for life sciences research.
|
|
| domain | founded_year | HQ Location |
Developer of cell culture media and ancillary reagents for life science research
|
|
| domain | founded_year | HQ Location |
Develops tools and products for research and clinical application
|
|
| domain | founded_year | HQ Location |
Provider of molecular diagnostic kits for cancer, hereditary diseases, and reproductive disorders
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Acd Bio
Frequently Asked Questions about ACD Bio
When was ACD Bio founded?
ACD Bio was founded in 2006.
Where is ACD Bio located?
ACD Bio is headquartered in Newark, United States. It is registered at Newark, New Jersey, United States.
Is ACD Bio a funded company?
ACD Bio is a funded company, having raised a total of $39.4M across 8 funding rounds to date. The company's 1st funding round was a Series B of $12M, raised on Sep 05, 2006.
What is the annual revenue of ACD Bio?
Annual revenue of ACD Bio is $576.82K as on Dec 31, 2020.
What does ACD Bio do?
Founded in 2006 and based in Newark, United States, operations focus on biotechnology for biomarker analysis. A proprietary RNAscope technology is utilized to detect and quantify RNA biomarkers at single-molecule sensitivity in situ. Clinical-grade assay development and biomarker validation services are offered, along with companion diagnostic support. Targeted therapies for cancer and other diseases are facilitated through the platform, which encompasses RNAscope probes, reagent kits, hybridization systems, and software.
Who are the top competitors of ACD Bio?
ACD Bio's top competitors include Abcam, Sino Biological and Meridian Bioscience.
What products or services does ACD Bio offer?
ACD Bio offers RNAscope Assay, BaseScope Assay, and miRNAscope Assay.
Who are ACD Bio's investors?
ACD Bio has 8 investors. Key investors include New Leaf Venture Partners, Bio-Techne, HHS, National Cancer Institute, and Kenson Ventures.